Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031707 · ClinicalTrials.gov registry record · Phase 3
Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
NCT00031707: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00031707 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 429 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031707, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
Study Summary
RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in treating cancer-related weight loss and loss of appetite. PURPOSE: Randomized phase III trial to compare the effectiveness of megestrol with or without an omega-3 fatty acid-enriched nutritional supplement to that of the omega-3 fatty acid-enriched nutritional supplement alone in treating patients who have cancer-related weight loss and lack of appetite.
Interventions
- OTHER placebo
- DRUG megestrol acetate
- DIETARY_SUPPLEMENT eicosapentaenoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2000-03 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
What the finished NCT00031707 record still lists
NCT00031707 is an interventional study that assigns participants to a tested intervention. The registered 429 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00031707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031707 about?
NCT00031707 is a clinical study titled "Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite". RATIONALE: Megestrol and /or an omega-3 fatty acid-enriched nutritional supplement may improve cancer-related weight loss and lack of appetite. It is not yet known whether megestrol alone, an omega-3 fatty acid-enriched nutritional supplement alone, or a combination of both is most effective in trea...
What is the current status of trial NCT00031707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2000-03. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00031707?
The interventions under investigation include: placebo (OTHER), megestrol acetate (DRUG), eicosapentaenoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00031707?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00031707's enrollment target sits among peer trials
429 878th of 2000 higher than 1,123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05932862 · 429 participants · Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia